Drug intelligence / Profile preview

Dingxin Recipe III

Development stage: Preclinical
Administration: Oral

Overview

Dingxin Recipe III (DXR III) is a traditional Chinese medicine (TCM) herbal compound formula primarily utilized for the treatment of hyperlipidemia and atherosclerosis. It exerts its therapeutic effects through multiple pathways, including the upregulation of hepatic steroidogenic acute regulatory protein-related lipid transfer domain containing 4 (Stard4) to restore lipid homeostasis and the enhancement of the intestinal gut barrier via the short-chain fatty acids (SCFAs)/G-protein coupled receptor 43 (GPR43) signaling pathway. Research indicates that DXR III effectively reduces lipid accumulation and ameliorates hyperlipidemic injury. It is currently used in clinical practice in China and has been studied in animal models to elucidate its pharmacological mechanisms.

Other names: Dingxin Recipe 3

Targets

FFAR2

Beyond the preview

Go deeper on Dingxin Recipe III.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dingxin Recipe III.

Explore the full profile